Coffee inhibits the reactivation of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1: A glucocorticoid connection in the anti-diabetic action of coffee?

FEBS Letters

Volumn 580, Issue 17, 2006, Pages 4081-4085

  Atanasov, Atanas G ^a   Dzyakanchuk, Anna A ^a   Schweizer, Roberto A S ^a   Nashev, Lyubomir G ^a   Maurer, Evelyne M ^a   Odermatt, Alex ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

11 Hydroxysteroid dehydrogenase; Coffee; Cortisol; Diabetes; Glucocorticoid

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ANTIDIABETIC AGENT; COFFEA ARABICA EXTRACT; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PLANT EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; COFFEE; DRUG ACTIVITY; DRUG EFFECT; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCONEOGENESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERMOSTABILITY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ACTIVE TRANSPORT, CELL NUCLEUS; CARBOXY-LYASES; CELL LINE; CELL NUCLEUS; COFFEA; COFFEE; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; GLUCONEOGENESIS; HUMANS; HYDROCORTISONE; PLANT EXTRACTS; RECEPTORS, GLUCOCORTICOID;

EID: 33745855823     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.06.046     Document Type: Article

References (33)

1. van Dam R.M., and Hu F.B. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 294 (2005) 97-104
2. van Dam R.M. Coffee and type 2 diabetes: from beans to beta-cells. Nutr. Metab. Cardiovasc. Dis. 16 (2006) 69-77
3. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 30 (2005) 1-10
4. Asensio C., Muzzin P., and Rohner-Jeanrenaud F. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int. J. Obes. Relat. Metab. Disord. 28 Suppl. 4 (2004) S45-S52
5. Tomlinson J.W. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target. Minerva Endocrinol. 30 (2005) 37-46
6. Paterson J.M., Seckl J.R., and Mullins J.J. Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289 (2005) R642-R652
7. Wang M. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr. Opin. Invest. Drugs 7 (2006) 319-323
8. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R., Seckl J.R., and Mullins J.J. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA 94 (1997) 14924-14929
9. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., and Seckl J.R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276 (2001) 41293-41300
10. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
11. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., Shinyama H., Sharp M.G., Fleming S., Mullins J.J., Seckl J.R., and Flier J.S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112 (2003) 83-90
12. Paterson J.M., Morton N.M., Fievet C., Kenyon C.J., Holmes M.C., Staels B., Seckl J.R., and Mullins J.J. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. USA 101 (2004) 7088-7093
13. Alberts P., Engblom L., Edling N., Forsgren M., Klingstrom G., Larsson C., Ronquist-Nii Y., Ohman B., and Abrahmsen L. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45 (2002) 1528-1532
14. Alberts P., Nilsson C., Selen G., Engblom L.O., Edling N.H., Norling S., Klingstrom G., Larsson C., Forsgren M., Ashkzari M., Nilsson C.E., Fiedler M., Bergqvist E., Ohman B., Bjorkstrand E., and Abrahmsen L.B. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144 (2003) 4755-4762
15. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., Le Grand C.B., Li Z., Metzger J.M., Mundt S.S., Noonan H., Nunes C.N., Olson S.H., Pikounis B., Ren N., Robertson N., Schaeffer J.M., Shah K., Springer M.S., Strack A.M., Strowski M., Wu K., Wu T., Xiao J., Zhang B.B., Wright S.D., and Thieringer R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202 (2005) 517-527
16. Odermatt A. 11beta-hydroxysteroid dehydrogenase type 1: a potential therapeutic target for the control of local glucocorticoid concentrations. Curr. Enzyme Inhib. 1 (2005) 97-105
17. Schweizer R.A., Atanasov A.G., Frey B.M., and Odermatt A. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol. Cell. Endocrinol. 212 (2003) 41-49
18. Yanagimoto K., Ochi H., Lee K.G., and Shibamoto T. Antioxidative activities of fractions obtained from brewed coffee. J. Agric. Food Chem. 52 (2004) 592-596
19. Atanasov A.G., Nashev L.G., Schweizer R.A., Frick C., and Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 571 (2004) 129-133
20. Carey K.L., Richards S.A., Lounsbury K.M., and Macara I.G. Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the Ran/TC4 GTPase mediates an essential function independent of nuclear protein import. J. Cell Biol. 133 (1996) 985-996
21. Odermatt A., Arnold P., Stauffer A., Frey B.M., and Frey F.J. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J. Biol. Chem. 274 (1999) 28762-28770
22. Arampatzis S., Kadereit B., Schuster D., Balazs Z., Schweizer R.A., Frey F.J., Langer T., and Odermatt A. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J. Mol. Endocrinol. 35 (2005) 89-101
23. Apostolova G., Schweizer R.A., Balazs Z., Kostadinova R.M., and Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E957-E964
24. Schuster D., Maurer E.M., Laggner C., Nashev L.G., Wilckens T., Langer T., and Odermatt A. The discovery of new 11b-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J. Med. Chem. 49 (2006) 3454-3466
25. Dorea J.G., and da Costa T.H. Is coffee a functional food?. Br. J. Nutr. 93 (2005) 773-782
26. Salazar-Martinez E., Willett W.C., Ascherio A., Manson J.E., Leitzmann M.F., Stampfer M.J., and Hu F.B. Coffee consumption and risk for type 2 diabetes mellitus. Ann. Intern. Med. 140 (2004) 1-8
27. Greenberg J.A., Axen K.V., Schnoll R., and Boozer C.N. Coffee, tea and diabetes: the role of weight loss and caffeine. Int. J. Obes. (Lond.) 29 (2005) 1121-1129
28. Battram D.S., Arthur R., Weekes A., and Graham T.E. The glucose intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men. J. Nutr. 136 (2006) 1276-1280
29. McCarty M.F. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med. Hypoth. 64 (2005) 848-853
30. Bhathena S.J., and Velasquez M.T. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am. J. Clin. Nutr. 76 (2002) 1191-1201
31. Seckl J.R., Morton N.M., Chapman K.E., and Walker B.R. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog. Horm. Res. 59 (2004) 359-393
32. Stewart P.M. Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome-11beta-hydroxysteroid dehydrogenase type 1. Clin. Med. 5 (2005) 142-146
33. Miguet L., Zhang Z., Barbier M., and Grigorov M.G. Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors. J. Comput. Aided Mol. Des. 20 (2006) 67-81